3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma, Large B-Cell, Diffuse
14
Lymphoma
12
Burkitt Lymphoma
12
Neoplasms
8
Lymphoma, Follicular
8
Lymphoma, B-Cell
6
Rhabdomyosarcoma
5
Medulloblastoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Hodgkin Disease
4
Retinoblastoma
3
Recurrence
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell, Marginal Zone
3
Central Nervous System Neoplasms
3
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma, Embryonal
2
Rhabdomyosarcoma, Alveolar
2
Rhabdoid Tumor
2
Neuroectodermal Tumors, Primitive
2
Lymphoproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma, AIDS-Related
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bendamustine Hydrochloride
2
sepantronium
1
acalabrutinib
1
Vincristine
1
Rituximab
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Bone Marrow Transplantation
1
ARQ531
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphatic Diseases
×
Vincristine
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled